FORTITUDE study met primary and key secondary endpoints of reduction in KHDC1L and creatine kinase levels, with safety profile consistent with previous results Del-brax indicates potential to become ...
Novartis to highlight Rhapsido® data across multiple immune-mediated diseases at EAACI Congress 2026
About Novartis Immunology At Novartis, we’re advancing bold science with the goal of bringing relief and a renewed sense of hope to people living with autoimmune diseases. Building on our legacy of ...
New Cosentyx® (secukinumab) data from REPLENISH, largest ever global Phase III trial in polymyalgia rheumatica, to be highlighted in oral session New ianalumab interim results from Sjögren’s Phase III ...
Growing improvement in major molecular response (MMR) rates demonstrated with Scemblix vs. all standard-of-care TKIs including imatinib and second generation (2G) TKIs 1 Clinically relevant 15.2% ...
Novartis’ commitment to kidney diseases Building on a legacy of more than 40 years that began in transplant, Novartis is on a mission to empower breakthroughs and transform care in kidney health, ...
studies were published in Nature Medicine. Following the CHMP’s recommendation for approval, the European Commission (EC) is expected to issue a final decision within approximately two months. About ...
Novartis has announced new long-term Social Impact & Sustainability (SI&S) targets and goals, reinforcing our commitment to go beyond breakthroughs to maximize the impact of our medicines to support ...
～2歳未満を対象としたゾルゲンスマ ® 点滴静注に次ぐ、SMAの新たな治療選択肢～ ノバルティス ファーマ株式会社（本社：東京都港区、代表取締役社長：ジョンポール・プリシーノ、以下 ...
Proposed acquisition supports the Novartis oncology strategy in hormone receptor positive, human epidermal growth factor receptor two-negative (HR+/HER2-) breast cancer The lead asset, SNV4818, ...
Imagine stepping into a space where cutting-edge technology meets life-changing impact. At Novartis we’re building something extraordinary – an Innovation Lab (iLab) where we are mastering the art and ...
Cosentyx is the only IL-17A inhibitor approved for this population, and the first differentiated mechanism in nearly a decade1-3 HS often emerges around puberty, underscoring importance of early ...
A Q&A with Jake Haling, Head of Oncology Drug Discovery in San Diego, on induced proximity and how it could open new paths to treat cancer. At Novartis Biomedical Research, oncology teams around the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results